Durvalumab and Lenvatinib in Participants With Advanced and Recurrent Endometrial Carcinoma

NCT04444193 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Endometrial Cancer

Interventions

DRUG: Durvalumab
DRUG: Lenvatinib Oral Product

Sponsor

Shanghai First Maternity and Infant Hospital